EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Recent Advances in Biomarkers for Diabetes Mellitus and Tuberculosis Comorbidity: A Comprehensive Review

Raj Kumar Mandal

International Journal of Sciences and Innovation Engineering · 2025

DOI: 10.70849/ijsci02092025130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Sciences and Innovation Engineering, 2025. Verfasst von Raj Kumar Mandal. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus (DM) is a major risk factor for tuberculosis (TB) which increasing the risk of active disease threefold and worsening treatment outcomes. The dual burden of DM-TB comorbidity complicates global health, particularly in low and middle income countries. Recent evidence highlights the role of biomarkers in early detection, monitoring and prognosis of DM-TB co-infection. These biomarkers include inflammatory cytokines, metabolic signatures, genetic polymorphisms, transcriptomic markers and imaging-based indicators that provide insights into host-pathogen interactions.

Objective

This review summarizes key advances in biomarker discovery and validation for DM-TB comorbidity, focusing on diagnostic, prognostic and therapeutic monitoring roles. Methodology: Literature was searched in PubMed, Scopus, Web of Science and WHO reports for studies published between 2020 to 2025 on biomarkers in D.M, T.B and their comorbidity. Both clinical and preclinical studies were analysed.

Results

Significant advances include transcriptomic signatures validated for DM-TB populations, metabolic markers such as altered lipid and amino acid profiles and cytokine signatures including IL-6, TNF-αand IFN-γ correlating with disease severity. Epigenetic markers & circulating microRNAs such as miR-29 and miR-155 emerged as promising non-invasive diagnostic tools. Imaging biomarkers using PET-CT and AI-supported radiomics have improved disease monitoring.

Conclusion

Biomarker discovery is reshaping DM-TB diagnosis and treatment. Integrated multi-omics and AI-assisted platforms promise personalized approaches though validation across diverse populations and affordable implementation remain challenges.

Zitieren

APA

Mandal, R. K. (2025). Recent Advances in Biomarkers for Diabetes Mellitus and Tuberculosis Comorbidity: A Comprehensive Review. International Journal of Sciences and Innovation Engineering. https://doi.org/10.70849/ijsci02092025130

Vancouver

Mandal RK. Recent Advances in Biomarkers for Diabetes Mellitus and Tuberculosis Comorbidity: A Comprehensive Review. International Journal of Sciences and Innovation Engineering. 2025. doi:10.70849/ijsci02092025130

BibTeX
@article{Mandal2025,
  author = {Mandal, Raj Kumar},
  title = {Recent Advances in Biomarkers for Diabetes Mellitus and Tuberculosis Comorbidity: A Comprehensive Review},
  journal = {International Journal of Sciences and Innovation Engineering},
  year = {2025},
  doi = {10.70849/ijsci02092025130}
}
Kostenlos starten →